Substituted aminotetralines
0 Assignments
0 Petitions
Accused Products
Abstract
The invention is concerned with the compounds of formula I:
and pharmaceutically acceptable salts and esters thereof, wherein R1-R4 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
-
Citations
26 Claims
-
1. A compound of formula I:
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
-
2. A compound of claim 1 wherein R3 is hydrogen.
-
3. A compound of claim 1 wherein R3 is methyl.
-
4. A compound of claim 1 wherein R4 is phenyl substituted by two substituents independently selected from the group consisting of:
- (1) halogen, and (2) lower alkyl optionally substituted by halogen.
-
5. A compound of claim 1 wherein R4 is phenyl substituted by two substituents independently selected from the group consisting of:
-
(1) fluoro; (2) chloro; (3) bromo; (4) lower alkyl (5) lower alkanoyl; (6) lower alkylsulfanyl, lower alkylsulfinyl, or lower alkylsulfonyl; (7) lower cycloalkylsulfanyl, lower cycloalkylsulfinyl, or lower cycloalkylsulfonyl; (8) trifluoromethyl, difluoromethyl, or fluoromethyl; and (9) 1,1-difluoroethyl.
-
-
6. A compound of claim 1 wherein R4 is phenyl substituted by two substituents independently selected from the group consisting of:
-
(1) fluoro; (2) chloro; (3) bromo; (4) methyl; (5) ethyl; (6) propyl or isopropyl; (7) butyl, sec-butyl, or tert-butyl; (8) trifluoromethyl, difluoromethyl, or fluoromethyl; and (9) 1,1-difluoroethyl.
-
-
7. A compound of claim 1 wherein R4 is phenyl substituted by two substituents independently selected from the group consisting of:
-
(1) fluoro; (2) chloro; (3) bromo; and (4) trifluoromethyl.
-
-
8. A compound of claim 1 wherein R4 is pyridine substituted by one substituent selected from the group consisting of:
-
(1) halogen; (2) lower alkyl optionally substituted by halogen; and (3) phenyl or pyridine, wherein said phenyl or pyridine is optionally substituted by lower alkyl.
-
-
9. A compound of claim 1 wherein R4 is pyridine substituted by phenyl wherein said phenyl is optionally substituted by lower alkyl.
-
10. A compound of claim 1 wherein R1 is hydrogen, fluoro, chloro, bromo, methoxy, or phenyl and R2 is hydrogen, fluoro, chloro, methyl, ethyl, propyl, or isopropyl;
- with the proviso that R1 and R2 are not both hydrogen.
-
11. A compound of claim 1 wherein R1 is hydrogen, fluoro, chloro, or bromo and R2 is hydrogen, fluoro, chloro, or methyl, ethyl, or isopropyl;
- with the proviso that R1 and R2 are not both hydrogen.
-
12. A compound of claim 1 wherein at least one of R1 or R2 is fluoro, chloro, or bromo.
-
13. A compound of claim 1 wherein R1 is fluoro or chloro.
-
14. A compound of claim 1 wherein R4 is phenyl substituted by two substituents at positions 3 and 5 on the phenyl ring where such positions are indicated below in formula IC:
-
15. A compound of claim 14 wherein R1 is fluoro or chloro;
- R2 is hydrogen or fluoro;
R3 is hydrogen; and
the phenyl ring is substituted at positions 3 and 5 as indicated in formula IC with substituents independently selected from the group consisting of fluoro, bromo, or trifluoromethyl.
- R2 is hydrogen or fluoro;
-
16. A compound of claim 14 wherein R1 is fluoro or chloro;
- R2 is hydrogen or fluoro;
R3 is hydrogen; and
the phenyl ring is substituted at positions 3 and 5 with trifluoromethyl.
- R2 is hydrogen or fluoro;
-
17. A compound of claim 1 which is an (R)-enantiomer as depicted in formula IA:
-
18. A compound of claim 1 selected from the group consisting of:
-
[(R)-5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-2,3-dichloro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-2-isopropyl-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-2-methyl-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-2-ethyl-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-3-chloro-2-methyl-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-3-chloro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-2-chloro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [(R)-5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-3-chloro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; 5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-3-chloro-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; and [3-Chloro-5-(2,5-dichloro-benzenesulfonylamino)-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; or a pharmaceutically acceptable salt or ester thereof.
-
-
19. A compound of claim 1 selected from the group consisting of:
-
[3-Chloro-5-(2,4-dichloro-benzenesulfonylamino)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; 5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-2,3-dichloro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [3-Chloro-5-(2,5-dichloro-benzenesulfonylamino)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [3-Chloro-5-(2,4-dichloro-benzenesulfonylamino)-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(3-Bromo-5-trifluoromethyl-benzenesulfonylamino)-3-chloro-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [3-Chloro-5-(3-fluoro-5-trifluoromethyl-benzenesulfonylamino)-5,6,7,8-Tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(3-Bromo-5-trifluoromethyl-benzenesulfonylamino)-3-chloro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [(R)-3-Chloro-5-(2,4-dichloro-benzenesulfonylamino)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-3-bromo-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; and [(R)-5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-3-bromo-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; or a pharmaceutically acceptable salt or ester thereof.
-
-
20. A compound of claim 1 selected from the group consisting of:
-
[3-Chloro-2-fluoro-5-(3-fluoro-5-trifluoromethyl-benzenesulfonylamino)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [(R)-5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-3-methoxy-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-3-phenyl-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [(R)-5-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-2-chloro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [2,3-Difluoro-5-(3-fluoro-5-trifluoromethyl-benzenesulfonylamino)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [3-Fluoro-5-(3-fluoro-5-trifluoromethyl-benzenesulfonylamino)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(3-Bromo-5-trifluoromethyl-benzenesulfonylamino)-3-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; 5-(3-Bromo-5-trifluoromethyl-benzenesulfonylamino)-2,3-difluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; and [5-(2,4-Dichloro-benzenesulfonylamino)-2,3-difluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; or a pharmaceutically acceptable salt or ester thereof.
-
-
21. A compound of claim 1 selected from the group consisting of:
-
[5-(2,4-Dichloro-benzenesulfonylamino)-3-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(2,5-Dichloro-benzenesulfonylamino)-2,3-difluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(2,5-Dichloro-benzenesulfonylamino)-3-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; {2,3-Difluoro-5-[5-(3-isopropyl-phenyl)-pyridine-2-sulfonylamino]-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {3-Fluoro-5-[5-(3-isopropyl-phenyl)-pyridine-2-sulfonylamino]-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {3-Chloro-5-[5-(3-isopropyl-phenyl)-pyridine-2-sulfonylamino]-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; [(R)-3-Bromo-5-(3-bromo-5-trifluoromethyl-benzenesulfonylamino)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [(R)-3-Chloro-2-fluoro-5-(3-fluoro-5-trifluoromethyl-benzenesulfonylamino)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [(R)-5-(3-Bromo-5-trifluoromethyl-benzenesulfonylamino)-3-chloro-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; and [(R)-3-Chloro-5-(2,4-dichloro-benzenesulfonylamino)-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; or a pharmaceutically acceptable salt or ester thereof.
-
-
22. A compound of claim 1 selected from the group consisting of:
-
[(R)-3-Chloro-5-(3-fluoro-5-trifluoromethyl-benzenesulfonylamino)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [(R)-5-(3-Bromo-5-trifluoromethyl-benzenesulfonylamino)-3-chloro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [(R)-3-Chloro-5-(2,5-dichloro-benzenesulfonylamino)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; {3-Chloro-2-fluoro-5-[5-(3-isopropyl-phenyl)-pyridine-2-sulfonylamino]-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; [5-(2,5-Dichloro-benzenesulfonylamino)-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [5-(2,4-Dichloro-benzenesulfonylamino)-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; {2-Fluoro-5-[5-(3-isopropyl-phenyl)-pyridine-2-sulfonylamino]-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; [(R)-3-Bromo-5-(2,5-dichloro-benzenesulfonylamino)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; [(R)-3-Bromo-5-(2,4-dichloro-benzenesulfonylamino)-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; and [5-(3,5-Bis-methanesulfonyl-benzenesulfonylamino)-3-bromo-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; or a pharmaceutically acceptable salt or ester thereof.
-
-
23. A compound of claim 1 selected from the group consisting of:
-
[5-(3,5-Bis-trifluoromethyl-benzenesulfonyl)-methyl-amino)-3-chloro-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy]-acetic acid; {5-[(3,5-Bis-trifluoromethyl-benzenesulfonyl)-methyl-amino]-2-methyl-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[(3,5-Bis-trifluoromethyl-benzenesulfonyl)-methyl-amino]-2-ethyl-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[(3,5-Bis-trifluoromethyl-benzenesulfonyl)-methyl-amino]-3-chloro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {(R)-5-[(3,5-Bis-trifluoromethyl-benzenesulfonyl)-methyl-amino]-3-chloro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {3-Chloro-5-[(2,4-dichloro-benzenesulfonyl)-methyl-amino]-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[(3,5-Bis-trifluoromethyl-benzenesulfonyl)-methyl-amino]-2,3-dichloro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[(3,5-Bis-trifluoromethyl-benzenesulfonyl)-methyl-amino]-3-chloro-2-methyl-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {3-Chloro-5-[(2,5-dichloro-benzenesulfonyl)-methyl-amino]-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; and {3-Chloro-5-[(2,5-dichloro-benzenesulfonyl)-methyl-amino]-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; or a pharmaceutically acceptable salt or ester thereof.
-
-
24. A compound of claim 1 selected from the group consisting of:
-
{3-Chloro-5-[(2,4-dichloro-benzenesulfonyl)-methyl-amino]-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[(3-Bromo-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-3-chloro-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[(3-Bromo-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-3-chloro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {3-Chloro-5-[(3-fluoro-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {3-Chloro-2-fluoro-5-[(3-fluoro-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[(2,4-Dichloro-benzenesulfonyl)-methyl-amino]-3-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[(3,5-Bis-trifluoromethyl-benzenesulfonyl)-methyl-amino]-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[(2,4-Dichloro-benzenesulfonyl)-methyl-amino]-2,3-difluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[(2,5-Dichloro-benzenesulfonyl)-methyl-amino]-3-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; and {5-[(3-Bromo-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-2,3-difluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; or a pharmaceutically acceptable salt or ester thereof.
-
-
25. A compound of claim 1 selected from the group consisting of:
-
{5-[(2,5-Dichloro-benzenesulfonyl)-methyl-amino]-2,3-difluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[(3-Bromo-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-3-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {3-Fluoro-5-[(3-fluoro-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {2,3-Difluoro-5-[(3-fluoro-5-trifluoromethyl-benzenesulfonyl)-methyl-amino]-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; (2,3-Difluoro-5-{[5-(3-isopropyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid; (3-Fluoro-5-{[5-(3-isopropyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid; (3-Chloro-5-{[5-(3-isopropyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid; (3-Chloro-2-fluoro-5-{[5-(3-isopropyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid; {5-[(2,5-Dichloro-benzenesulfonyl)-methyl-amino]-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; {5-[(2,4-Dichloro-benzenesulfonyl)-methyl-amino]-2-fluoro-5,6,7,8-tetrahydro-naphthalen-1-yloxy}-acetic acid; and (2-Fluoro-5-{[5-(3-isopropyl-phenyl)-pyridine-2-sulfonyl]-methyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-acetic acid; or a pharmaceutically acceptable salt or ester thereof.
-
-
26. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
-
2. A compound of claim 1 wherein R3 is hydrogen.
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeHoffmann-La Roche Incorporated (Roche Holding AG)
-
Original AssigneeHoffmann-La Roche Incorporated (Roche Holding AG)
-
InventorsFirooznia, Fariborz, Gillespie, Paul, Goodnow, Robert Alan Jr., Lin, Tai-An, Sidduri, Achyutharao, So, Sung-Sau, Tan, Jenny
-
Primary Examiner(s)Zucker, Paul A
-
Application NumberUS12/540,839Publication NumberTime in Patent Office1,125 DaysField of SearchNoneUS Class Current514/562CPC Class CodesA61P 11/00 Drugs for disorders of the ...A61P 11/02 Nasal agents, e.g. deconges...A61P 11/06 AntiasthmaticsA61P 17/00 Drugs for dermatological di...A61P 37/08 Antiallergic agents antiast...A61P 43/00 Drugs for specific purposes...C07C 2602/10 the other ring being six-me...C07C 311/20 having the nitrogen atom of...C07C 311/29 having the sulfur atom of a...C07C 317/14 having sulfone or sulfoxide...C07D 213/34 to which a second hetero at...